Targeting the integrated stress response in hematologic malignancies
Open Access
- 8 November 2022
- journal article
- review article
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 11 (1) , 1-15
Abstract
While numerous targeted therapies have been recently adopted to improve the treatment of hematologic malignancies, acquired or intrinsic resistance poses a significant obstacle to their efficacy. Thus, there is increasing need to identify novel, targetable pathways to further improve therapy for these diseases. The integrated stress response is a signaling pathway activated in cancer cells in response to both dysregulated growth and metabolism, and also following exposure to many therapies that appears one such targetable pathway for improved treatment of these diseases. In this review, we discuss the role of the integrated stress response in the biology of hematologic malignancies, its critical involvement in the mechanism of action of targeted therapies, and as a target for pharmacologic modulation as a novel strategy for the treatment of hematologic malignancies.Keywords
Funding Information
- Hospital Research Foundation
- National Health and Medical Research Council (1184485)
This publication has 105 references indexed in Scilit:
- ER-stress-induced transcriptional regulation increases protein synthesis leading to cell deathNature Cell Biology, 2013
- ER stress–mediated autophagy promotes Myc-dependent transformation and tumor growthJournal of Clinical Investigation, 2012
- Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer targetNature Chemical Biology, 2011
- Both Transcriptional Regulation and Translational Control of ATF4 Are Central to the Integrated Stress ResponseJournal of Biological Chemistry, 2010
- The mechanism of eukaryotic translation initiation and principles of its regulationNature Reviews Molecular Cell Biology, 2010
- Double-Stranded RNA-Dependent Protein Kinase Links Pathogen Sensing with Stress and Metabolic HomeostasisCell, 2010
- Double-Stranded RNA-Dependent Protein Kinase-Dependent Apoptosis Induction by a Novel Small CompoundThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myelomaBlood, 2008
- Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cellsBlood, 2006
- Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cellsProceedings of the National Academy of Sciences, 2004